FDA resources can help prescribers better understand biosimilars

January 19, 2018
by Leah Christl, PhD The Biologics Price Competition and Innovation Act, included within the Affordable Care Act, established an abbreviated…

Multivitamins may reduce risk for chemotherapy-induced peripheral neuropathy

January 17, 2018
Multivitamin supplements may reduce incidence of chemotherapy-induced peripheral neuropathy among women undergoing treatment with paclitaxel for…

Study underway to evaluate immunotherapy plus radiation for newly diagnosed sarcoma

January 16, 2018
A clinical trial is underway to assess use of two immunotherapy agents, durvalumab and tremelimumab, plus radiation therapy for the treatment of…

Opioid use associated with nonadherence to adjuvant endocrine therapy among breast cancer survivors

January 15, 2018
Opioid use appeared significantly associated with nonadherence to adjuvant endocrine therapy among a cohort of breast cancer survivors, according to…

Inhaled iloprost may prevent cancer progression among former smokers

December 28, 2017
A trial at University of Colorado Cancer Center is designed to evaluate the potential of an inhaled form of the pulmonary hypertension drug iloprost…

Trial assesses CD22 CAR T-cell therapy for children, young adults with acute lymphoblastic leukemia

December 27, 2017
The PLAT-04 clinical trial is underway to evaluate the use of CD22 chimeric antigen receptor T-cell immunotherapy for children and young adults with…

High failure rate of phase 3 glioblastoma trials highlights need for greater reliability of earlier studies

December 5, 2017
Results of a study published in Neuro-Oncology indicate a high failure rate of phase 3 trials for glioblastoma, the most common primary malignant…

Multistakeholder partnership will assess advances in hemophilia treatment

November 28, 2017
Researchers, patients, policymakers, payer representatives and government agencies are working together to seek consensus on a core set of evaluation…
In the Journals PlusPerspective

Copanlisib confers rapid, durable responses for advanced lymphoma

November 27, 2017
Copanlisib, a phosphatidylinositol 3-kinase inhibitor, induced objective responses among pretreated patients with relapsed or refractory indolent…

Multinational study to compare three regimens for first-line treatment of advanced renal cell carcinoma

November 22, 2017
A multinational study is underway to compare three treatment strategies for patients with previously untreated advanced or metastatic kidney cancer…